Celestica’s SWOT analysis: stock gains momentum on AI growth

Celestica beat Q4 and full-year 2025 expectations, then raised FY2026 guidance by about $1B and announced a fivefold increase in 2026 capex to support AI infrastructure and hyperscale cloud demand. Analysts have been lifting estimates, with FY2026 EPS views ranging from $5.95 to $8.77 and FY2027 from $6.87 to $12.21, while price targets were also raised. The stock remains highly valued at 44.3x earnings, but the article frames the growth outlook and backlog as supportive of further upside.

Analysis

CLS is becoming a levered expression of hyperscaler capex, but the cleaner read is that the market is repricing the entire AI infrastructure supply chain around capacity scarcity rather than end-demand alone. If Celestica is expanding capex this aggressively, the bottleneck is shifting from customer demand to manufacturing throughput, which should disproportionately benefit adjacent suppliers of substrates, connectors, test equipment, and industrial automation tools over the next 6-12 months.

The first-order winner is CLS, but the second-order winners are the ecosystem names that sell into factory buildouts and networking density upgrades; the losers are lower-quality EMS peers that lack the balance sheet or customer mix to match this pace without margin dilution. The more interesting bearish implication is for hyperscaler hardware OEMs with weaker execution, because a more capacity-constrained supply base tends to reward incumbents with allocation discipline and punish late entrants via longer lead times and worse pricing.

The risk is that the stock is now trading on a “perfect cadence” narrative: strong orders, seamless capex deployment, and no digestion in AI spend. That combination rarely holds beyond a few quarters; if hyperscaler budgets normalize even modestly in the next 2-3 earnings cycles, the market will likely compress the multiple before the earnings catch-up arrives. In other words, the near-term setup is still positive, but the upside is increasingly dependent on continued estimate revisions rather than just execution.

Consensus appears to be underestimating how much of this story is already a forward capacity bet, not a current earnings story. That argues for owning the trend, but not chasing outright — the best entry is likely after any quarter where capex causes gross margin or free cash flow to wobble, because the market should treat that as a setup for future revenue acceleration rather than an immediate deterioration if backlog remains intact.

Key Decisions for Investors

• Long CLS on 3-6 month horizon into next print, but size modestly; the risk/reward remains favorable while estimates are still being revised up, yet the forward multiple is vulnerable if execution slips.
• Buy call spreads in CLS for the next 2 earnings cycles rather than outright shares; this captures upside from another guidance raise while capping valuation downside if the market starts to de-rate growth.
• Pair long CLS vs short a weaker EMS peer with less AI exposure and lower margin quality over the next 6-12 months; the thesis is allocation advantage and customer concentration advantage, not just sector beta.
• Add a basket long in supply-chain beneficiaries that monetize capex expansion (connectivity, test, factory automation) over 6-12 months; the second-order winners often re-rate earlier than the headline assembler.
• Set a tactical trim level on CLS after any post-earnings gap-up; if the market starts paying for perfection, the cleanest trade is to monetize momentum and re-enter on capex-related drawdowns.